• and asthma attacks-caused by vasoactive hormones secreted by metastases from carcinoid tumors. (medscape.com)
  • Carcinoid tumors arise from neuroendocrine cells, which are widespread in the human body, especially in the organs derived from the primitive intestine (see the image below). (medscape.com)
  • Carcinoid tumors and related syndromes may be a part of multiple endocrine neoplasia . (medscape.com)
  • Typically, 90% of carcinoid tumors originate from the distal ileum or appendix (the embryologic midgut. (medscape.com)
  • [ 4 ] ) Carcinoid tumors represent 90% of appendiceal tumors. (medscape.com)
  • Carcinoids do not produce the malignant carcinoid syndrome until they are no longer confined to the small bowel or mesentery, perhaps because the liver breaks down the secretory products of tumors restricted to those locations. (medscape.com)
  • If a patient is thought to have carcinoid syndrome, blood and urine tests must be performed to determine levels of bioactive substances secreted by carcinoid tumors. (medscape.com)
  • Bochemical diagnosis of carcinoid tumors is based on the measurement of the serotonin metabolite 5-HIAA in urine. (medscape.com)
  • Scintigraphy with indium-111 diethylenetriamine pentaacetic acid (DTPA) octreotide (In-111 DTPA Octr), or OctreoScan, localizes the primary carcinoid and eventual recurrences, as well as other neuroendocrine tumors, with high sensitivity and specificity. (medscape.com)
  • The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. (harvard.edu)
  • Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. (harvard.edu)
  • Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. (harvard.edu)
  • About two-thirds of carcinoid tumors occur in the GI tract. (qualityhealth.com)
  • According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. (openpr.com)
  • Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. (openpr.com)
  • Therapeutic options in patients with advanced-stage gastroenteropancreatic (GEP) neuroendocrine tumors are limited. (snmjournals.org)
  • Therapeutic options in patients with progressive and disseminated metastatic neuroendocrine gastroenteropancreatic (GEP) tumors are often limited, and prognosis is often poor ( 1 , 2 ). (snmjournals.org)
  • Because 111 In emits short-range electrons that can have significant biologic effects at a cellular level ( 17 - 19 ), radionuclide therapy with a high activity of 111 In-pentetreotide has been used in a few patients with GEP tumors ( 5 , 20 - 30 ). (snmjournals.org)
  • We report the results of radionuclide therapy with either 111 In-pentetreotide or 131 I-MIBG in a population of patients with advanced-stage GEP tumors. (snmjournals.org)
  • Thus, the term "carcinoid" was replaced by the term "gastroenteropancreatic neuroendocrine tumors, GEP-NETs"[ 2 ]. (wjgnet.com)
  • Overview of Carcinoid Tumors Carcinoid tumors develop from neuroendocrine cells in the gastrointestinal tract (90%), pancreas, pulmonary bronchi, and rarely the genitourinary tract. (msdmanuals.com)
  • Endocrinologically active tumors of the diffuse peripheral endocrine or paracrine system (neuroendocrine tumors) produce various amines and polypeptides with corresponding symptoms and signs, including carcinoid syndrome. (msdmanuals.com)
  • Serotonin , the primary hormone produced by carcinoid tumors, acts on smooth muscle to cause diarrhea, colic, and malabsorption. (msdmanuals.com)
  • Understanding carcinoid tumors, carcinoid syndrome , and treatments for carcinoid when surgery is not an option are the focus of three feature articles by Ellen Greenlaw on WebMD.com this month. (carcinoid.org)
  • Neuroendocrine tumors (NETs) associated with carcinoid syndrome (CS) overproduce serotonin, mediated by tryptophan hydroxylase-1 (TPH1). (analysisgroup.com)
  • the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. (guidelinecentral.com)
  • A somatostatin analog is a medication that mimics the function of somatostatin and can reduce the production and release of substances by tumors that cause carcinoid syndrome. (netrf.org)
  • Surgical removal of tumors in the small intestine can be complicated by difficulties or delays in diagnosis or the tumor's secretion of hormones Despite this complexity, surgery to remove the tumor can extend the life of the patient. (netrf.org)
  • Carcinoid syndrome - Patients with foregut carcinoid tumors may suffer from carcinoid syndrome, which classically manifests with gastrointestinal complaints. (logicalimages.com)
  • As opposed to foregut carcinoid tumors, patients with midgut tumors typically demonstrate a more cyanotic flushing. (logicalimages.com)
  • Carcinoid syndrome develops in about 50% of the population with neuroendocrine tumors ( 1 ). (snmjournals.org)
  • For treatment of neuroendocrine cancers (i.e., carcinoid tumors and pancreatic endocrine tumors) involving the liver. (aetna.com)
  • Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen , said:"The new indication for Somatuline ® Depot offers patients in the U.S. a valuable treatment option for debilitating carcinoid syndrome associated with neuroendocrine tumors. (cloudfront.net)
  • Diarrhea is often a presenting symptom in patients with neuroendocrine tumors. (advancedpractitioner.com)
  • Signs and symptoms of carcinoid tumors vary greatly and depend on the location and size of the tumor and on the presence of metastases. (medscape.com)
  • Because carcinoid tumors are rare in children, clinicians rely on reports of adult patients to understand the full scope of the manifestations of the disease. (medscape.com)
  • Ectopic adrenocorticotropic hormone (ACTH) and Cushing syndrome observed with foregut carcinoid tumors must be differentiated from other tumors that produce these symptoms. (medscape.com)
  • Likewise, rare acromegaly caused by the carcinoid tumors must be differentiated from pituitary tumors. (medscape.com)
  • An early and frequent (94%) symptom of carcinoid tumors, especially those of midgut with metastases, is cutaneous flushing, which typically affects the head and neck. (medscape.com)
  • [ 4 ] but Oberndorfer called a group of small, benign-appearing tumors karzinoide tumoren (carcinoid) for the first time in 1907. (medscape.com)
  • The name was chosen to separate these tumors from ordinary malignancies (carcinomas), but by the 1950s, the fact that carcinoids could be malignant was obvious, thanks to Erspamer and Asero (1952), who identified serotonin production by carcinoid tumors. (medscape.com)
  • In 1914, Gosset and Masson demonstrated that carcinoid tumors might arise from enterochromaffin cells (Kulchitsky cell) within glands of Lieberkühn using silver impregnation techniques. (medscape.com)
  • In 1928, Masson established characterization of carcinoids as argentaffin cell tumors. (medscape.com)
  • In 1980, the World Health Organization (WHO) applied the term carcinoid to all tumors of the diffuse endocrine system (synonymous with amine precursor uptake and decarboxylation [APUD] and neuroendocrine cell system). (medscape.com)
  • Gastrointestinal (GI) neuroendocrine tumors (also called gastrointestinal carcinoid tumors) form from a certain type of neuroendocrine cell (a type of cell that is like a nerve cell and a hormone-making cell). (navigatingcare.com)
  • Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the Surveillance, Epidemiology, and End Results Program. (cancercentrum.se)
  • Malignant carcinoid syndrome occurs in fewer than 10% of patients with a carcinoid tumor. (medscape.com)
  • Follow-up assays of other bioactive substances vary according to the location of the carcinoid tumor. (medscape.com)
  • The somatostatin analogs (SSAs) octreotide and lanreotide are used to control carcinoid symptoms and tumor progression in advanced inoperable disease. (medscape.com)
  • A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. (harvard.edu)
  • In a broad sense, these syndromes are collections of symptoms that result from substances produced by the tumor, and they occur remotely from the tumor itself. (medscape.com)
  • In other cases, paraneoplastic syndromes result from the production and release of physiologically active substances by the tumor. (medscape.com)
  • Carcinoid heart disease (CHD) is a rare and potentially lethal manifestation of an advanced carcinoid (neuroendocrine) tumor. (karger.com)
  • Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. (openpr.com)
  • For instance, in 2009, a study by Journal of Clinical Oncology, showed 4 to 5 out of every 100,000 people are diagnosed with a neuroendocrine tumor and over 100,000 people suffering from neuroendocrine tumor in the U.S., also most individual suffering from carcinoid are asymptomatic until the tumor is fully developed. (openpr.com)
  • The intent was to treat all patients because of uncontrolled tumor disease ( n = 21), contraindication to chemotherapy or surgery ( n = 7), or uncontrolled and badly tolerated clinical symptoms ( n = 4). (snmjournals.org)
  • The syndrome results from vasoactive substances (including serotonin , bradykinin, histamine, prostaglandins, polypeptide hormones) secreted by the tumor, which is typically a metastatic intestinal carcinoid. (msdmanuals.com)
  • An intestinal carcinoid does not usually cause carcinoid syndrome unless hepatic metastases have occurred because metabolic products released by the tumor are rapidly destroyed by blood and liver enzymes in the portal circulation (eg, serotonin by hepatic monoamine oxidase). (msdmanuals.com)
  • Luncheon with the Experts in New York City - Carcinoid and Neuroendocrine Tumor Patients Are Invited! (carcinoid.org)
  • We conducted a real-world clinical practice study to explore the effects of TE on tumor growth in patients with NETs and CS. (analysisgroup.com)
  • Surgery is generally reserved for patients in which 90% of the tumor can be removed and who do not have compromised liver function or extensive liver metastases. (netrf.org)
  • For patients with heavy tumor burden and metastases, tumor debulking (removing large portions of the tumor) may improve symptoms as well as extend and improve the overall health of the patient. (netrf.org)
  • We report the gratifying response of functioning metastatic neuroendocrine tumor with carcinoid heart disease (uncontrolled by long-acting octreotide) to treatment with 177 Lu-DOTATATE. (snmjournals.org)
  • A 30-y-old man who had been diagnosed with a grade II jejunal neuroendocrine tumor metastatic to the liver and abdomen was found clinically and on 2-dimensional (2D) echocardiography to have the complication of carcinoid heart disease. (snmjournals.org)
  • The syndrome occurs when a rare cancerous tumor called a carcinoid tumor secretes certain chemicals into the bloodstream. (srnnews.com)
  • Findings range from no tumor-related findings to full symptoms of carcinoid syndrome. (medscape.com)
  • Diagnostic difficulties may arise in patients who have flushing without a large tumor or metastases and in those without symptoms. (medscape.com)
  • A constellation of symptoms called malignant carcinoid syndrome is often associated with this tumor. (medscape.com)
  • Carcinoid syndrome may occur if the tumor spreads to the liver or other parts of the body. (navigatingcare.com)
  • If the tumor has spread to the liver and the liver enzymes cannot destroy the extra hormones made by the tumor, high amounts of these hormones may remain in the body and cause carcinoid syndrome. (navigatingcare.com)
  • It may also be used in the treatment of serotonin syndrome. (wikipedia.org)
  • The hormone serotonin is broken down in the liver to 5-HIAA, and the levels of this can be raised in the blood or urine of patients with a diagnosis of NET. (christie.nhs.uk)
  • Carcinoid syndrome occurs in patients with neuroendocrine tumours that release hormones such as serotonin. (europa.eu)
  • Like somatostatin, it blocks the release of gastrointestinal and endocrine hormones (such as serotonin) involved in carcinoid syndrome and is expected to prevent the symptoms of carcinoid syndrome. (europa.eu)
  • Xermelo mainly targets the overproduction of serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea. (openpr.com)
  • The histopathologic features were similar to those observed in carcinoid-induced valvular disease, a serotonin-related syndrome. (cdc.gov)
  • The function of somatostatin is to inhibit (reduce or limit) the release of gastrointestinal and endocrine hormones in the body, some of which are substances (e.g., serotonin) that contribute to carcinoid syndrome. (netrf.org)
  • Malignant Carcinoid Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
  • This graph shows the total number of publications written about "Malignant Carcinoid Syndrome" by people in Harvard Catalyst Profiles by year, and whether "Malignant Carcinoid Syndrome" was a major or minor topic of these publication. (harvard.edu)
  • Below are the most recent publications written about "Malignant Carcinoid Syndrome" by people in Profiles. (harvard.edu)
  • They are defined as clinical syndromes involving nonmetastatic systemic effects that accompany malignant disease. (medscape.com)
  • [ 6 ] to the malignant carcinoid syndrome . (medscape.com)
  • Carcinoid syndrome due to a malignant somatostatinoma. (bioseek.eu)
  • Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. (harvard.edu)
  • Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. (harvard.edu)
  • Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. (harvard.edu)
  • The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. (openpr.com)
  • Because symptoms frequently occur relatively late during the course of valvular incompetence, the prevalence of valve lesions was assessed for patients who were exposed to these drugs but who had no obvious history of cardiac disease or cardiac symptoms. (cdc.gov)
  • Metabolic products released by primary pulmonary and ovarian carcinoids bypass the portal route and may similarly induce symptoms. (msdmanuals.com)
  • Rare intestinal carcinoids with only intra-abdominal spread can drain directly into the systemic circulation or the lymphatics and cause symptoms. (msdmanuals.com)
  • Octreotide) to control symptoms of carcinoid syndrome that are difficult to or cannot be controlled with a somatostatin analog alone. (netrf.org)
  • If liver metastases can be surgically removed, it often leads to the improvement of carcinoid syndrome symptoms. (netrf.org)
  • Mast cell activation syndrome - The more recently termed mast cell activation syndrome (MCAS) describes patients who have multiple mast cell mediator-induced symptoms that do not meet the WHO criteria (see Best Tests) for diagnosis of systemic mastocytosis when other underlying diseases have been excluded. (logicalimages.com)
  • This response favorably altered the clinical course of the patient, enabling corrective valvular surgery, enhancing health-related quality of life, improving symptoms (from New York Heart Association grade III at baseline to grade I after 6 cycles), stabilizing the disease, and substantially reducing the level of 5-hydroxyindole acetic acid. (snmjournals.org)
  • Production of vasoactive intestinal peptide (VIP) may produce symptoms similar to those of neuroblastoma, which is far more prevalent than carcinoid in children. (medscape.com)
  • Patients developed symptoms after a median of 16 days (range 2-120 days) and were asymptomatic after 68 days (mean, range 27-93 years). (medscape.com)
  • Patients with diarrhea that is not controlled with somatostatin analog therapy can be treated with telostristat ethyl, a tryptophan hydroxylase inhibitor. (medscape.com)
  • Methysergide is also used in carcinoid syndrome to treat severe diarrhea. (wikipedia.org)
  • Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome diarrhea treatment devices. (openpr.com)
  • This in turn is expected to fuel growth of the carcinoid syndrome diarrhea treatment market. (openpr.com)
  • In February 2017, Lexicon Pharmaceutical Inc., announced that the U.S. Food and Drug Administration (FDA) approved Xermelo (Telotristat etiprate) as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy (SSA) for adults. (openpr.com)
  • Development of first-of-its-kind therapeutic approach to treat carcinoid syndrome diarrhea creates highly lucrative growth opportunities for market players. (openpr.com)
  • However, low awareness and certain side effects associated with this therapy are expected to hinder growth of the carcinoid syndrome diarrhea treatment market. (openpr.com)
  • The drug is used in combination with a somatostatin analog to control diarrhea associated with carcinoid syndrome. (netrf.org)
  • Malabsorption syndromes such as lactose intolerance, gluten malabsorption (celiac disease), and other food intolerances can cause diarrhea. (woosterhospital.org)
  • Irritable bowel syndrome (IBS) is a very common gastrointestinal disorder that causes alternating periods of diarrhea and constipation. (woosterhospital.org)
  • Less common causes of diarrhea include Zollinger-Ellison Syndrome, neuropathy, and carcinoid syndrome. (woosterhospital.org)
  • Diarrhea and malabsorption occur in as many as 84% of patients. (medscape.com)
  • Diarrhea is abolished or significantly reduced in 75% of patients, flushing improves in 100% wheezing in 100% with a decrease in airways resistance, and in one patient myopathy has improved. (johnshopkins.edu)
  • A universal definition of diarrhea does not exist, although patients seem to have no difficulty defining their own situation. (medscape.com)
  • Diarrhea is one of the most common reasons patients seek medical care. (medscape.com)
  • The diagnosis was clear, the prognosis uncertain: Carcinoid Syndrome and carcinoid tumours. (patientconfessions.com)
  • When a patient without a known cancer presents with one of the "typical" paraneoplastic syndromes, a diagnosis of cancer should be considered and investigated. (medscape.com)
  • The level of this hormone can be raised in patients with a diagnosis of NET, or in patients taking proton pump inhibitors (tablets to reduce acid production in the stomach) and can be measured in the blood. (christie.nhs.uk)
  • Khan MS, Walter T, Buchanan-Hughes A, Worthington E, Keeber L, Feuilly M, Grande E. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review. (wjgnet.com)
  • All patients underwent diagnostic paracentesis, which confirmed the diagnosis. (medscape.com)
  • The PAN Foundation today opened a new patient assistance program for people living with carcinoid syndrome. (curetoday.com)
  • Oral medications that act upon specific cell signaling pathways (such as mTOR, VEGF, VEGF-A) may be used in combination with other approaches to treat carcinoid syndrome. (netrf.org)
  • The pathophysiology of paraneoplastic syndromes is complex and intriguing. (medscape.com)
  • Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid . (carcinoid.org)
  • Two hundred patients were enrolled, most (61%) had well-differentiated gastrointestinal NETs (61%) and received TE for an average of 12 months (SD, 7.3). (analysisgroup.com)
  • 12. Patients who are unable to take oral medication or having a gastrointestinal disease likely to interfere with drug absorption (including malnutrition and stomach flu). (who.int)
  • Pheochromocytoma - Patients with an underlying pheochromocytoma present with paroxysms of hypertension, tachycardia, and diaphoresis. (logicalimages.com)
  • See full prescribing information for dosage adjustment in patients with acromegaly and renal or hepatic impairment. (guidelinecentral.com)
  • Aside from the symptomatic treatment of carcinoid syndrome due to neuroendocrine tumours and acromegaly, BIM 23A760 may reduce the tumour size, Ipsen said. (pharmaceutical-technology.com)
  • The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly and carcinoid syndrome. (fiercebiotech.com)
  • The trial studied the oral drug in "biochemically controlled" patients who were on injections such as octreotide or lanreotide for the disorder known as acromegaly, in which the body produces an excess of growth hormone. (srnnews.com)
  • Crinetics expects to report results in the first quarter of 2024 from another late-stage trial evaluating paltusotine in treatment-naïve acromegaly patients. (srnnews.com)
  • Pending results from the study, it plans to submit an application to the U.S. Food and Drug Administration next year, seeking regulatory approval for the drug for all acromegaly patients. (srnnews.com)
  • Furthermore, in 2017, Ipsen Biopharmaceutical, announced the U.S. Food and Drug Administration (FDA) approval for a supplemental indication of Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of short-acting somatostatin analogue rescue therapy. (openpr.com)
  • SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. (somatulinedepot.com)
  • Both Octreotide and Lanreotide have similar effectiveness and provide symptom relief in 50% to 70% of people with carcinoid syndrome. (netrf.org)
  • The additional Somatuline ® Depot approval for carcinoid syndrome was based on "Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (ELECT): A Randomized, Double-Blind, Placebo-Controlled Trial," published in Endocrine Practice. (cloudfront.net)
  • For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177) with Octreotate . (carcinoid.org)
  • During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. (europa.eu)
  • No clinical trials with the medicine in patients with carcinoid syndrome had been started. (europa.eu)
  • Dr Edelman and colleagues studied the gap between clinical trial and real-world results in patients with type 2 diabetes who used GLP-1 receptor agonists, comparing results from 11 randomized, phase 3 studies of GLP-1 receptor agonists and DPP-4 inhibitors versus real-world data from the Optum/Humedica database of patients with similar characteristics. (ahdbonline.com)
  • Karos has completed the single ascending dose portion of its 120-patient Phase 1 clinical trial in healthy volunteers and is now conducting the multiple ascending dose portion of the study, with the goal of reporting results from the Phase 1 program in the middle of this year. (nlvpartners.com)
  • Karos Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company advancing innovative medicines for patients living with rare diseases, including fibrotic, inflammatory, and metabolic diseases. (nlvpartners.com)
  • The duration of tuberculosis treatment depends on the regimen chosen, the patient's clinical and radiographical responses, smear and culture results, and susceptibility of Mycobacterium tuberculosis isolates from the patient or the suspected source case. (who.int)
  • However, linezolid should be used with special caution in patients with severe renal insufficiency, and only when the anticipated benefit is considered to outweigh the theoretical risk, because the clinical significance of higher exposure (up to 10 fold) to the two primary metabolites of linezolid is unknown. (who.int)
  • Ipsen has initiated two Phase II clinical studies to evaluate the efficacy and safety of BIM 23A760, a new drug to treat patients suffering from carcinoid syndrome due to neuroendocrine tumours. (pharmaceutical-technology.com)
  • The most common clinical presentation for a small intestinal carcinoid is periodic abdominal pain, which can be caused by fibrosis of the mesentery, kinking of the bowel, or intestinal obstruction. (medscape.com)
  • A review is given on the clinical features of carcinoid syndrome including symtomatology, diagnostics, biochemistry and treatment. (johnshopkins.edu)
  • A gender-driven clinical management of these patients should be advisable. (bvsalud.org)
  • Hepatic artery embolization is effective only in patients with large liver metastases but has no impact on extrahepatic disease ( 4 ). (snmjournals.org)
  • This side effect has been estimated to occur in 1/5000 patients. (wikipedia.org)
  • Most pNENs occur sporadically, but in some cases, pNENs may occur as part of a larger genetic syndrome such as multiple endocrine neoplasia type 1 (MEN1) or von Hippel Lindau (VHL) syndrome. (rarediseases.org)
  • In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. (somatulinedepot.com)
  • Carcinoid crisis can occur spontaneously or as a response to stress, such as anesthesia or chemotherapy. (medscape.com)
  • Wheezing or asthmalike syndrome is caused by bronchial constriction and may occur in as many as 25% of patients. (medscape.com)
  • A section (on the right) of an intestinal carcinoid mass arising from the mucosa (150 X). Image courtesy of Professor Pantaleo Bufo, University of Foggia, Italy. (medscape.com)
  • For patient education information, see the Cancer Center , as well as Lung Cancer , Lymphoma , and Carcinoid Syndrome . (medscape.com)
  • Treatment focuses on control of the underlying carcinoid syndrome, targeting subsequent valvular heart disease and managing consequent heart failure. (karger.com)
  • Cryptococcosis is a well-recognised infection in immunocompromised patients, although its prevalence varies with the type of immune defect. (annals.edu.sg)
  • In early September, FDA received echocardiographic reports from five independent, unpublished echocardiographic prevalence surveys of patients who had received dexfenfluramine or fenfluramine alone or in combination with phentermine ( Table 1 ). (cdc.gov)
  • The duration of exposure to the drugs was determined for patients based on the time they were treated by the centers providing the prevalence survey data. (cdc.gov)
  • Carcinoid heart disease manifests in many patients with carcinoid syndrome ( 2 ), but the prevalence dropped to approximately 20% after the introduction of newer therapies such as somatostatin analogs and 177 Lu-DOTATATE, along with everolimus, sunitinib, and the combination of capecitabine and temozolomide ( 3 ). (snmjournals.org)
  • Night sweats are a common experience, with a prevalence of up to 41% among primary care patients. (aafp.org)
  • A systematic review found that the cross-sectional prevalence of night sweats ranges from 10% to 41% in the primary care setting, with the highest prevalence occurring in patients between 41 and 55 years of age. (aafp.org)
  • Night sweats are a nonspecific symptom that patients commonly experience but rarely discuss with their physicians without prompting. (aafp.org)
  • 1 The definition of night sweats varies and generally does not require that the symptom be bothersome to the patient. (aafp.org)
  • In one study conducted in the primary care research setting, only 12% of patients who were explicitly asked about night sweats reported the symptom to their physicians. (aafp.org)
  • Aggressive systemic mastocytosis, in which there is organ destruction from a mast cell infiltrate, is rare and should promote investigation for mast cell leukemia or other hematologic disorders such as myelodysplastic syndromes, myeloproliferative or myelodysplastic disorders, acute myeloid leukemia, and chronic myeloproliferative neoplasia. (logicalimages.com)
  • The causes of the paraneoplastic syndromes associated with underlying cancers are not well known. (medscape.com)
  • and (3) other malignancies which are commonly developed in patients with appendiceal NETs. (wjgnet.com)
  • Single-arm, pre/post chart review study of patients with advanced NETs who received TE for ≥6 months and had ≥2 radiological scans within 12 months before and ≥1 scan after TE initiation. (analysisgroup.com)
  • Surgical treatments aim to remove or reduce the volume of NETs, causing carcinoid syndrome. (netrf.org)
  • This new indication for Somatuline ® Depot gives doctors the only somatostatin analog approved by the FDA in adults for both improving progression-free survival in patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic GEP-NETs and for the treatment of carcinoid syndrome," said Cynthia Schwalm, Executive Vice-President, and President, North American Commercial Operations, Ipsen . (cloudfront.net)
  • This medicine was designated as an orphan medicine for the treatment of carcinoid syndrome in the European Union on 13 January 2023. (europa.eu)
  • Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. (harvard.edu)
  • In a patient who is already receiving treatment for cancer, the onset of a paraneoplastic syndrome may be an indication of relapse. (medscape.com)
  • Not generally used in the treatment of patients who have had surgery for a NET. (christie.nhs.uk)
  • A study that explores whether a treatment or device is safe and effective in humans, or to compare the results of patients taking a new treatment with the results of patients taking the standard treatment to determine if one treatment is better than the other. (christie.nhs.uk)
  • To overcome the carcinoid crisis, treatment options may considered such as surgery, chemotherapy, targeted radionuclide therapy, radiofrequency ablation, and chemoembolization on the basis of patient-by-patient. (openpr.com)
  • Carcinoid syndrome being a rare condition, there are very few if any treatment options available. (openpr.com)
  • Although the initial intent was that all patients would undergo treatment, a subset of patients was not treated for reasons pertaining to nonmedical considerations. (snmjournals.org)
  • Results were consistent in a subgroup of patients with the same documented NET treatment before and after initiating TE. (analysisgroup.com)
  • the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. (guidelinecentral.com)
  • SOMATULINE DEPOT is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. (guidelinecentral.com)
  • Care should be taken when initiating treatment in patients with bradycardia. (somatulinedepot.com)
  • Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis-B viral replication (presence of DNA of hepatitis-B virus (HBV-DNA) and hepatitis-B antigen (HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and / or fibrosis. (europa.eu)
  • Based on this progress, the Company anticipates commencing a Phase 2 study of KAR5585 as a once-a-day treatment in patients with PAH. (nlvpartners.com)
  • A next-generation TPH1 inhibitor also is being advanced for the treatment of carcinoid syndrome. (nlvpartners.com)
  • Typically, a total treatment duration of 18-20 months and a treatment duration of 15-17 months after culture conversion are suggested for most patients, with the duration being modified according to the patient's response to therapy. (who.int)
  • Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery? (snmjournals.org)
  • Considering the significantly shortened overall survival of patients with carcinoid heart disease, the relative paucity of available treatment options, and the risk of complications during corrective surgery on poorly controlled functioning disease, 177 Lu-DOTATATE can emerge as a potent option in this group of patients. (snmjournals.org)
  • This condition can be life threatening, but treatment with somatostatin analog SMS-201-995 has improved the outcome of patients with carcinoid crisis. (medscape.com)
  • CONCLUSION: Using combined anesthesia in patients subjected to PRP appeared to reduce pain perception limiting the treatment duration and the interruptions for pain without significant complications. (bvsalud.org)
  • The aim of this review is to discuss the main aspects of the treatment of these patients to provide a practical approach for clinicians. (bvsalud.org)
  • We present a patient with somatostatinoma in which an immunocytochemical study of the specimens from pancreas and liver showed a weak positive reaction for gastrin besides a strong positive reaction for somatostatin. (bioseek.eu)
  • Hyperthermic intraperitoneal chemotherapy (HIPEC), commonly referred to as the chemo bath," may offer an alternative option for patients with advanced forms of abdominal cancer. (qualityhealth.com)
  • Neutrophilic eccrine hidradenitis (NEH) is a neutrophilic dermatosis primarily affecting the eccrine glands and occurs most commonly in patients undergoing chemotherapy for a malignancy. (annals.edu.sg)
  • First-line choice of systemic chemotherapy has no obvious effect in half of the patients, and second-line rescue chemotherapy is effective in no more than a few patients. (snmjournals.org)
  • There are a variety of carcinoid syndrome treatments, including somatostatin analogs and other medications, liver-directed therapies, surgery, and chemotherapy. (netrf.org)
  • A persistent and intense salmon-pink to red flushing occurs in these patients. (logicalimages.com)
  • Focal hyperhidrosis occurs in otherwise healthy patients commonly before the age of 25 years, 5 and roughly two-thirds of patients report a positive family history. (racgp.org.au)
  • We report a case of carcinoid heart disease that was managed successfully by such therapy ( 177 Lu-DOTATATE), with a documented objective and symptomatic response that enabled the patient to be considered for corrective surgery. (snmjournals.org)
  • The initial 2 cycles of 177 Lu-DOTATATE brought about impressive symptomatic improvement, and the patient went on to receive a total of 6 cycles with a cumulative dose of 37.40 GBq. (snmjournals.org)
  • Particularly noteworthy was a remarkable improvement in the symptomatic scale, with the patient being asymptomatic for dyspnea at that point (from New York Heart Association grade III at baseline to grade I after 6 cycles) and with a substantial reduction of urinary 5-hydroxyindole acetic acid (5-HIAA) to nearly one sixth the baseline level. (snmjournals.org)
  • Initiate appropriate medical management in patients with symptomatic bradycardia. (cloudfront.net)
  • The intermittent manual bolus thermodilution method is the most common means of determining cardiac output in critically ill patients. (annals.edu.sg)
  • In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia. (somatulinedepot.com)
  • elevated human chorionic gonadotropin and pancreatic polypeptide levels are occasionally present with carcinoids. (msdmanuals.com)
  • Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. (harvard.edu)
  • Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. (harvard.edu)
  • a patient with ovarian teratomas, whose secretory products enter into the systemic circulation, may present with this syndrome without liver metastasis. (medscape.com)
  • Mast cell leukemia is seen in two-thirds of patients with aggressive systemic mastocytosis and portends rapid progression that could potentially result in multi-organ failure. (logicalimages.com)
  • of these, three patients died after surgery. (cdc.gov)
  • We compared the efficacy of radionuclide therapy with 111 In-pentetreotide and 131 I-metaiodobenzylguanidine (MIBG) in 20 patients (group A) with the outcome of similar patients who could not be treated for nonmedical reasons (group B, n = 12). (snmjournals.org)
  • Radionuclide therapy was beneficial in 14 patients (73% of group A), with only 1 significant side effect. (snmjournals.org)
  • The overall Kaplan-Meier survival rate and cumulative progression-free and cumulative event-free survival rates during the first 15 mo were significantly higher in patients receiving radionuclide therapy ( P = 0.019, P = 0.024, and P = 0.019, respectively). (snmjournals.org)
  • Radionuclide therapy is feasible and safe and significantly defers the occurrence of fatal and nonfatal events in patients clinically uncontrolled by conventional therapy. (snmjournals.org)
  • Consequently, radionuclide therapy may be proposed to patients with uncontrolled disease after conventional therapy ( 5 , 11 ). (snmjournals.org)
  • With the growing use of 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), there are many unanswered questions regarding patient selection. (snmjournals.org)
  • Patients with chronic diseases, such as type 2 diabetes, hyperlipidemia, or hypertension, have to take their medications long-term to maintain control of their chronic condition. (ahdbonline.com)
  • Angioedema in a patient with neuroendocrine tumour. (harvard.edu)
  • In patients with insulinomas, the tumour produces abnormally high levels of insulin, which causes low blood sugar levels (hypoglycaemia). (christie.nhs.uk)
  • In 1907, Oberndorfer[ 1 ] first introduced the term "carcinoid" to describe "little carcinomas" of the small intestine which were thought (by him at that time) to be probably benign. (wjgnet.com)
  • Critically important will be to develop new treatments that can alter the course of disease and deliver improvements in patient survival and quality of life. (nlvpartners.com)
  • There is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than haemodialysis). (who.int)
  • The additional approval also confirms Ipsen's commitment to developing research-driven treatments intended to help provide patients battling cancer with new therapy options. (cloudfront.net)
  • Some research suggests that leaky gut syndrome, or increased intestinal permeability, is implicated in dozens of diseases including arthritis. (qualityhealth.com)
  • Over the past 30 years, it has become a powerful advocacy voice for all patients with rare diseases, including cancer. (curetoday.com)
  • European Organisation for Rare Diseases (EURORDIS) , a non-governmental alliance of patient organisations and individuals active in the field of rare diseases. (europa.eu)
  • Orphanet , a database containing information on rare diseases, which includes a directory of patients' organisations registered in Europe. (europa.eu)
  • they receive extra support and attention, such as additional provider visits, frequent monitoring and follow-up, and access to educational resources, which can encourage patients to take their medication during the study, which is a finite period, whereas in the real world, patients with chronic diseases have to take the drug forever. (ahdbonline.com)
  • With PAH as our lead disease target, we are also advancing programs in pulmonary fibrosis unrelated to PAH, other diseases associated with fibrosis, and carcinoid syndrome. (nlvpartners.com)